Next Article in Journal
Community Pharmacists’ Beliefs about Suboptimal Practice during the Times of COVID-19
Next Article in Special Issue
The Effect of Genotyping on the Number of Pharmacotherapeutic Gene–Drug Interventions in Chronic Kidney Disease Patients
Previous Article in Journal
Application of Exploratory Factor Analysis and Item Response Theory to Validate NHANES ADL Scale in Patients Reporting Rheumatoid Arthritis
Previous Article in Special Issue
A Guide to a Pharmacist-Led Pharmacogenetic Testing and Counselling Service in an Interprofessional Healthcare Setting
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Experience, Knowledge, and Perceptions of Pharmacogenomics among Pharmacists and Nurse Practitioners in Alberta Hospitals

by
Meagan Hayashi
1,2,* and
Chad A. Bousman
3,4,5
1
Pharmacy Services, Alberta Health Services, Edmonton, AB T6G 2R3, Canada
2
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada
3
Departments of Medical Genetics, Psychiatry, Physiology & Pharmacology, Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada
4
Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, AB T2N 1N4, Canada
5
Mathison Centre for Mental Health Research and Education, Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 1N4, Canada
*
Author to whom correspondence should be addressed.
Pharmacy 2022, 10(6), 139; https://doi.org/10.3390/pharmacy10060139
Submission received: 22 September 2022 / Revised: 18 October 2022 / Accepted: 21 October 2022 / Published: 26 October 2022
(This article belongs to the Special Issue The Emerging Role of Pharmacists in Pharmacogenomics)

Abstract

Background: Despite evidence of clinical utility and the availability of prescription guidelines, pharmacogenomics (PGx) is not broadly used in institutional settings in Canada. To inform future implementation, this study aimed to identify healthcare provider knowledge, experience, and perceptions of PGx in Alberta, Canada. Methods: An online 44-item survey was distributed to pharmacists, nurse practitioners, and physicians employed or contracted with Alberta Health Services from January to May 2022. Questions included: demographics, professional history, PGx education and exposure, knowledge, and ability to use PGx, and attitudes towards, feasibility, clinical utility, education, and implementation. Results: Ninety-one pharmacists, 37 nurse practitioners, and 6 physicians completed the survey. Fifty-nine percent had 10 or more years of experience, and 71% practiced in urban settings. Only one-third had training in PGx, and one-quarter had used PGx. Most respondents (63%) had no knowledge of PGx resources, including the Pharmacogenomics Knowledge Base (75%), or the Clinical Pharmacogenetics Implementation Consortium guidelines (85%). While participants agreed that they understood genetic (75%) and PGx (63%) concepts, most disagreed with their ability regarding practical applications of PGx such as translating genotype to phenotype (74%) or counselling patients on results (66%). Participants agreed on the clinical utility of PGx in preventing adverse drug reactions (80%) and enhancing medication efficacy (77%), and identified oncology (62%), cardiovascular/stroke (60%), and psychiatry (56%) as therapeutic areas to consider implementation. At present, healthcare provider knowledge (87%), cost (81%), and limited guidelines/evidence (70%) are seen as the greatest barriers to implementation. Conclusion: Alberta healthcare providers have limited training, experience, or knowledge in PGx. However, most appear to have a positive outlook regarding clinical utility, especially within oncology, cardiology, and psychiatry. More effort is required to socialize the availability and quality of evidence and guidelines for the interpretation of PGx test results, address other knowledge gaps, and improve financial limitations.
Keywords: pharmacogenomics; pharmacogenetics; hospital pharmacy; pharmacist; nurse practitioner; physician; healthcare pharmacogenomics; pharmacogenetics; hospital pharmacy; pharmacist; nurse practitioner; physician; healthcare

Share and Cite

MDPI and ACS Style

Hayashi, M.; Bousman, C.A. Experience, Knowledge, and Perceptions of Pharmacogenomics among Pharmacists and Nurse Practitioners in Alberta Hospitals. Pharmacy 2022, 10, 139. https://doi.org/10.3390/pharmacy10060139

AMA Style

Hayashi M, Bousman CA. Experience, Knowledge, and Perceptions of Pharmacogenomics among Pharmacists and Nurse Practitioners in Alberta Hospitals. Pharmacy. 2022; 10(6):139. https://doi.org/10.3390/pharmacy10060139

Chicago/Turabian Style

Hayashi, Meagan, and Chad A. Bousman. 2022. "Experience, Knowledge, and Perceptions of Pharmacogenomics among Pharmacists and Nurse Practitioners in Alberta Hospitals" Pharmacy 10, no. 6: 139. https://doi.org/10.3390/pharmacy10060139

APA Style

Hayashi, M., & Bousman, C. A. (2022). Experience, Knowledge, and Perceptions of Pharmacogenomics among Pharmacists and Nurse Practitioners in Alberta Hospitals. Pharmacy, 10(6), 139. https://doi.org/10.3390/pharmacy10060139

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop